Julia Hoellenriegel

2.3k citations

18 papers · 1.4k indexed · 1 hit paper · h-index 10

Co-authors: Michael J. Keating William G. Wierda Jan A. Burger Hagop M. Kantarjian Mariela Sivina Susan O’Brien Brian J. Lannutti Sarah Meadows
Topics: Chronic Lymphocytic Leukemia Research (16 papers)Immunodeficiency and Autoimmune Disorders (4 papers)Glycosylation and Glycoproteins Research (3 papers)
Cited by: Genetics Pathology and Forensic Medicine Hematology
Journals: Blood PLoS ONE The Lancet Oncology
Partner nations: United States Germany Italy

In The Last Decade

Julia Hoellenriegel

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers

Countries citing papers authored by Julia Hoellenriegel

Since Specialization

Citations

This map shows the geographic impact of Julia Hoellenriegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Hoellenriegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Hoellenriegel more than expected).

Fields of papers citing papers by Julia Hoellenriegel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Hoellenriegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Hoellenriegel. The network helps show where Julia Hoellenriegel may publish in the future.

Co-authorship network of co-authors of Julia Hoellenriegel

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Hoellenriegel. A scholar is included among the top collaborators of Julia Hoellenriegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Hoellenriegel. Julia Hoellenriegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL 2016 ·Blood ·Dan A. Landau,Clare Sun,Daniel Rosebrock,(unknown),Sarah E. M. Herman,Julia Hoellenriegel,Mohammed Farooqui,Wandi Zhang,Donna Neuberg,Dimitri Livitz,Ignaty Leshchiner,Gad Getz,Jan A. Burger,Adrian Wiestner,Catherine J. Wu	2
2	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study 2014 ·The Lancet Oncology ·Jan A. Burger,Michael J. Keating,William G. Wierda,Elena Hartmann,Julia Hoellenriegel,Nathalie Y. Rosin,Iris de Weerdt,Ghayathri Jeyakumar,Alessandra Ferrajoli,Marylou Cárdenas-Turanzas,Susan Lerner,Jeffrey L. Jorgensen,Graciela M. Nogueras‐González,Gracy Zacharian,Xuelin Huang,Hagop M. Kantarjian,Naveen Garg,Andreas Rosenwald,Susan O’Brien	260
3	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells 2013 ·PLoS ONE ·Stefania Fiorcari,Wells S. Brown,Bradley W. McIntyre,Zeev Estrov,Rossana Maffei,Susan O’Brien,Mariela Sivina,Julia Hoellenriegel,William G. Wierda,Michael J. Keating,Wei Ding,Neil E. Kay,Brian J. Lannutti,Roberto Marasca,Jan A. Burger	75
4	Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition 2013 ·Blood ·Jan A. Burger,Dan A. Landau,Julia Hoellenriegel,Carrie Sougnez,Matthias Schlesner,Naveed Ishaque,Benedikt Brors,Michael J. Keating,William G. Wierda,Kristian Cibulskis,Hagop M. Kantarjian,Susan O’Brien,Donna Neuberg,Thorsten Zenz,Gad Getz,Catherine J. Wu	22
5	Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab 2013 ·Blood ·Julia Hoellenriegel,Elena Hartmann,Andreas Rosenwald,Susan O’Brien,Michael J. Keating,William G. Wierda,Joseph J. Buggy,Jan A. Burger	1
6	The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization 2013 ·Blood ·Julia Hoellenriegel,Dirk Zboralski,Christian Maasch,Nathalie Y. Rosin,William G. Wierda,Michael J. Keating,Anna Kruschinski,Jan A. Burger	179
7	Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients 2013 ·Blood ·Jan A. Burger,Michael J. Keating,William G. Wierda,Julia Hoellenriegel,Ghayathri Jeyakumar,Alessandra Ferrajoli,Stefan Faderl,Marylou Cárdenas-Turanzas,Susan Lerner,Gracy Zacharian,Xuelin Huang,Hagop M. Kantarjian,Susan O’Brien	36
8	Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration 2012 ·Leukemia ·Julia Hoellenriegel,Greg Coffey,Uma Sinha,(unknown),Mariela Sivina,Alessandra Ferrajoli,Farhad Ravandi,William G. Wierda,Susan O’Brien,Michael J. Keating,JA Burger	114
9	The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients 2012 ·Blood ·Jan A. Burger,Michael J. Keating,William G. Wierda,Julia Hoellenriegel,Alessandra Ferrajoli,Stefan Faderl,Susan Lerner,Gracy Zacharian,Xuelin Huang,Danelle F. James,Joseph J. Buggy,Hagop M. Kantarjian,Susan O’Brien	42
10	Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization 2012 ·Blood ·Dirk Zboralski,Julia Hoellenriegel,Christian Maasch,Anna Kruschinski,Jan A. Burger	2
11	In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial 2012 ·Blood ·Julia Hoellenriegel,Susan O’Brien,Michael J. Keating,William G. Wierda,Joseph J. Buggy,Jan A. Burger	4
12	The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiabreakdown → 2011 ·Blood ·Julia Hoellenriegel,Sarah Meadows,Mariela Sivina,William G. Wierda,Hagop M. Kantarjian,Michael J. Keating,Neill A. Giese,Susan O’Brien,Albert S. Yu,Langdon L. Miller,Brian J. Lannutti,Jan A. Burger	442
13	The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures. 2011 ·Blood ·Stefania Fiorcari,Wells S. Brown,Bradley W. McIntyre,Susan O’Brien,Mariela Sivina,Julia Hoellenriegel,William G. Wierda,Michael J. Keating,Roberto Marasca,Brian J. Lannutti,Zeev Estrov,Jan A. Burger	2
14	The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration, 2011 ·Blood ·Julia Hoellenriegel,Dirk Zboralski,Zeev Estrov,William G. Wierda,Michael J. Keating,Anna Kruschinski,Jan A. Burger	3
15	Nucleoporin 153 Arrests the Nuclear Import of Hepatitis B Virus Capsids in the Nuclear Basket 2010 ·PLoS Pathogens ·(unknown),Alexandra Schwarz,Michael Foss,Lixin Zhou,Birgit Rabe,Julia Hoellenriegel,Miriam Stoeber,Nelly Panté,Michael Kann	125
16	Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia 2010 ·Blood ·Julia Hoellenriegel,Sarah Meadows,William G. Wierda,Michael J. Keating,Brian J. Lannutti,Jan A. Burger	7
17	Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia 2010 ·Blood ·Julia Hoellenriegel,Greg Coffey,Uma Sinha,(unknown),William G. Wierda,Michael J. Keating,Jan A. Burger	1
18	Abnormal Vessel Formation in the Choroid of Mice Lacking Tissue Inhibitor of Metalloprotease-3 2008 ·Investigative Ophthalmology & Visual Science ·Andreas Janßen,Julia Hoellenriegel,(unknown),Heinrich Schrewe,Mathias W. Seeliger,Ernst R. Tamm,Andreas Ohlmann,Christian Albrecht May,Bernhard H. F. Weber,(unknown)	56

About Julia Hoellenriegel

Julia Hoellenriegel is a scholar working on Genetics, Hematology and Immunology, having authored 18 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (16 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Genetics (900 citations), Pathology and Forensic Medicine (656 citations) and Hematology (305 citations). Julia Hoellenriegel has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Michael J. Keating, William G. Wierda, Jan A. Burger, Hagop M. Kantarjian, Mariela Sivina, Susan O’Brien, Brian J. Lannutti, Sarah Meadows, Albert S. Yu and Neill A. Giese. Their work appears in journals such as Blood, PLoS ONE and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact